Adjuvant systemic therapy for intermediate and large gastric gastrointestinal stromal tumors (GISTs): Is there a survival benefit following margin negative surgical resection?

Published:October 11, 2019DOI:



      The value of adjuvant systemic therapy after margin-negative resection for gastric gastrointestinal stromal tumors (GISTs) remains unclear.


      The National Cancer Data Base was queried to identify patients undergoing margin negative resections for gastric GISTs >2 cm between 2010 and 2015. Patients were stratified by tumor size (small: 2.1–5 cm, intermediate: 5.1–10 cm, large: >10 cm), histologic grade (low: ≤5 mitoses/50 HPF and high: >5 mitoses/50 HPF), and use of adjuvant therapy. Multivariable cox proportional hazard methods were used to compare overall survival (OS).


      3520 patients met inclusion criteria. Adjuvant therapy was associated with a statistical improvement in OS (86% vs. 76%, p = 0.014) for those with large tumors but had no measurable effect in patients with small or intermediate sized tumors. On multivariable analysis, this association was independent of grade.


      Adjuvant therapy is associated with improved OS for patients with gastric GISTs >10 cm but provides no statistically significant benefit in OS for those with GISTs 2–10 cm


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Joensuu H.
        • Eriksson M.
        • Sundby Hall K.
        • et al.
        One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
        J Am Med Assoc. 2012 Mar 28; 307 (PubMed PMID: 22453568. Epub 2012/03/29): 1265-1272
        • Joensuu H.
        • Hohenberger P.
        • Corless C.L.
        Gastrointestinal stromal tumour.
        Lancet. 2013 Sep 14; 382 (PubMed PMID: 23623056. Epub 2013/04/30): 973-983
        • Dematteo R.P.
        • Gold J.S.
        • Saran L.
        • et al.
        Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).
        Cancer. 2008 Feb 1; 112 (PubMed PMID: 18076015. Epub 2007/12/14): 608-615
        • Sodergren S.C.
        • White A.
        • Efficace F.
        • et al.
        Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group.
        Crit Rev Oncol Hematol. 2014 Jul; 91 (PubMed PMID: 24495942. Epub 2014/02/06): 35-46
        • Cole A.L.
        • Dusetzina S.B.
        Generic price competition for specialty drugs: too little, too late?.
        Health Aff (Millwood). 2018 May; 37 (PubMed PMID: 29733710. Epub 2018/05/08): 738-742
        • Laurent M.
        • Brahmi M.
        • Dufresne A.
        • et al.
        Adjuvant therapy with imatinib in gastrointestinal stromal tumors (GISTs)-review and perspectives.
        Transl Gastroenterol Hepatol. 2019; 4 (PubMed PMID: 31143845. Pubmed Central PMCID: PMC6509420. Epub 2019/05/31): 24
        • Bilimoria K.Y.
        • Stewart A.K.
        • Winchester D.P.
        • Ko C.Y.
        The National Cancer Data Base: a powerful initiative to improve cancer care in the United States.
        Ann Surg Oncol. 2008 Mar; 15 (PubMed PMID: 18183467. Pubmed Central PMCID: PMC2234447. Epub 2008/01/10): 683-690
        • Dematteo R.P.
        • Ballman K.V.
        • Antonescu C.R.
        • et al.
        Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
        Lancet. 2009 Mar 28; 373 (PubMed PMID: 19303137. Pubmed Central PMCID: PMC2915459. Epub 2009/03/24): 1097-1104
        • Corless C.L.
        • Ballman K.V.
        • Antonescu C.R.
        • et al.
        Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.
        J Clin Oncol. 2014 May 20; 32 (PubMed PMID: 24638003. Pubmed Central PMCID: PMC4026579. Epub 2014/03/19): 1563-1570
        • Casali P.G.
        • Le Cesne A.
        • Poveda Velasco A.
        • et al.
        Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: a European organisation for research and treatment of cancer soft tissue and bone sarcoma group intergroup randomized trial in collaboration with the Australasian gastro-intestinal trials group, UNICANCER, French sarcoma group, Italian sarcoma group, and Spanish group for research on sarcomas.
        J Clin Oncol. 2015 Dec 20; 33 (PubMed PMID: 26573069. Epub 2015/11/18): 4276-4283
        • Sineshaw H.M.
        • Jemal A.
        • Lin C.C.
        • et al.
        Contemporary patterns and survival outcome of adjuvant systemic therapy for localized gastrointestinal stromal tumors.
        Am J Clin Oncol. 2017 Aug; 40 (PubMed PMID: 25599316. Epub 2015/01/20): 399-404